Immunovant News - IMVT

Company Name	Stock Ticker Symbol	Market	Type
Immunovant Inc	IMVT	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	-0.11	-0.39%	28.32	20:00:00

Open Price	Low Price	High Price	Close Price	Prev Close
28.21	27.99	29.22	28.32	28.43

more quote information »

Recent News

Date	Time	Source	Heading
3/12/2024	07:30	GLOBE	Immunovant Awarded U.S. Patent for IMVT-1402
2/23/2024	16:21	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/23/2024	16:16	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/23/2024	16:11	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/14/2024	08:47	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
2/12/2024	07:05	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2/12/2024	07:02	EDGAR2	Form 8-K - Current report
1/29/2024	16:11	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/19/2024	16:04	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/16/2024	07:29	EDGAR2	Form 3 - Initial statement of beneficial ownership of..
1/12/2024	16:34	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/09/2024	16:20	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/09/2024	16:18	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/09/2024	08:08	EDGAR2	Form 8-K - Current report
1/03/2024	08:00	GLOBE	Immunovant to Present at the 42nd Annual J.P. Morgan..
12/20/2023	17:40	DJN	Immunovant Gets Positive Data From Graves' Disease Treatment..
12/20/2023	16:37	EDGAR2	Form 8-K - Current report
12/20/2023	16:30	GLOBE	Immunovant Reports Positive Initial Phase 2 Results for..
11/28/2023	07:43	EDGAR2	Form 8-K - Current report
11/28/2023	07:00	GLOBE	Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD..
11/24/2023	14:55	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/24/2023	14:51	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/24/2023	14:47	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/24/2023	14:45	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/13/2023	08:00	GLOBE	Immunovant to Present at Upcoming Investor Conferences
11/09/2023	08:49	EDGAR2	Form S-3ASR - Automatic shelf registration statement of..
11/09/2023	07:13	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/09/2023	07:06	EDGAR2	Form 8-K - Current report
11/09/2023	07:00	GLOBE	Immunovant Reports Financial Results and Provides Corporate..
10/20/2023	16:06	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/11/2023	16:11	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/06/2023	17:15	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/06/2023	17:10	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/02/2023	16:52	GLOBE	Immunovant Announces Closing of Upsized Common Stock..
9/29/2023	16:48	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
9/28/2023	17:23	EDGAR2	Form 8-K - Current report
9/28/2023	06:09	EDGAR2	Form FWP - Filing under Securities Act Rules 163/433 of free..
9/27/2023	23:41	GLOBE	Immunovant Announces Pricing of $450 Million Common Stock..
9/26/2023	17:28	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
9/26/2023	17:00	GLOBE	Immunovant Announces Proposed Offering of $300 Million of..
9/26/2023	07:45	EDGAR2	Form 8-K - Current report
9/26/2023	06:00	GLOBE	Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD..
9/25/2023	23:01	GLOBE	Immunovant to Host Conference Call and Webcast to Report..
9/01/2023	16:08	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/25/2023	17:03	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/25/2023	17:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/25/2023	16:57	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/23/2023	16:48	EDGAR2	Form 8-K - Current report
8/16/2023	16:11	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/10/2023	07:19	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]